Key Takeaway: Rigel Pharmaceuticals will announce its third quarter 2025 financial results on November 4, 2025. Following the announcement, a live conference call and webcast will be held at 4:30 p.m. ET to discuss the results and provide a business update. Participants can join via phone or through the company's website.
Price reaction · baseline $29.69 (2025-10-28 close) · hit pre-market · 1 other RIGL headline(s) in the window, move may be shared
day 0 close · peak
-1%
Market Sentiment Analysis
POSITIVE FACTORS
Rigel will report its financial results, indicating ongoing business activity.
The live conference call allows for direct communication with management.
The webcast will be archived for future access, enhancing transparency.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+9%
120-day peak, hindsight
Typical move
12.1%
average across 2 past catalysts
Lead asset
Fostamatinib
Phase 2 · Acute Respiratory Distress Syndrome
Full Press Release Details
SOUTH SAN FRANCISCO, Calif.,Oct. 29, 2025/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its third quarter 2025 financial results after market close on Tuesday, November 4, 2025. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results and give an update on the business.
Participants can access the live conference call by dialing 877-407-3088 (domestic) or 201-389-0927 (international). The conference call and accompanying slides will also be webcast live and can be accessed from the Investor Relations section of the company's website atwww.rigel.com. The webcast will be archived and available for replay for 90 days after the call via the Rigel website.
About RigelRigel Pharmaceuticals, Inc. (Nasdaq:RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Company's marketed products and pipeline of potential products, visitwww.rigel.com.
Contact for Investors & Media:Investors:Rigel Pharmaceuticals, Inc.650.624.1232[email protected]